Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ER-819762 is an antagonist of the prostaglandin E2 (PGE2; Item No. 14010) receptor subtype EP4 (IC50 = 70 nM).1 It is selective for EP4 over EP1, EP2, and EP3 in a cAMP reporter assay at 10 µM. ER-819762 reduces differentiation of mouse helper T cells when used at concentrations ranging from 0.1 to 10 nM and decreases IL-23 secretion by mouse dendritic cells from 0.04 to 5 nM. It also reduces the levels of Marek's disease virus (MDV) in chicken embryonic fibroblasts (CEFs) when used at a concentration of 1 µM.2 Oral administration of ER-819762 (30 and 100 mg/kg) prevents and reverses paw swelling, edema, and inflammation in a mouse model of rheumatoid arthritis induced by glucose-6-phosphate isomerase (GPI).1
WARNING This product is not for human or veterinary use.
1. A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br. J. Pharmacol. 160(2), 292-310 (2010).
2. Replication of Marek’s disease virus is dependent on synthesis of de novo fatty acid and prostaglandin E2. J. Virol. 93(13), e00352-00319 (2109).